Archives

  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10

    • Y-27632 Dihydrochloride: Selective ROCK Inhibitor for Rho...

    2026-01-27

    Y-27632 Dihydrochloride: Selective ROCK Inhibitor for Rho/ROCK Pathway Modulation

    Executive Summary: Y-27632 dihydrochloride is a highly selective inhibitor of Rho-associated protein kinases, ROCK1 and ROCK2, with IC50 values of approximately 140 nM and 300 nM, respectively (APExBIO). The compound exhibits over 200-fold selectivity against other kinases, including PKC and MLCK (MolecularBeacon.net). By targeting the ROCK pathway, Y-27632 modulates actin cytoskeletal organization and inhibits Rho-mediated stress fiber formation (Dian et al., 2025). It is cell-permeable, highly soluble, and widely used in protocols enhancing stem cell survival and suppressing tumor invasion. Benchmarks confirm concentration-dependent effects on proliferation and viability in both in vitro and in vivo models.

    Biological Rationale

    Rho-associated protein kinases (ROCK1 and ROCK2) are serine/threonine kinases downstream of the small GTPase RhoA. These kinases modulate actin cytoskeletal organization, cell migration, adhesion, and contractility. Dysregulated ROCK activity is implicated in cancer progression, metastasis, and stem cell differentiation (Dian et al., 2025). Selective ROCK inhibition is a validated strategy for dissecting Rho/ROCK signaling in both basic and translational research. Y-27632 dihydrochloride, supplied by APExBIO (SKU: A3008), is widely adopted due to its specificity and reproducibility (product page). For a comprehensive review of cytoskeletal modulation, see this article; the present article expands on application-specific parameters and storage.

    Mechanism of Action of Y-27632 dihydrochloride

    Y-27632 dihydrochloride inhibits the catalytic domains of ROCK1 (IC50 ≈ 140 nM) and ROCK2 (Ki ≈ 300 nM), preventing phosphorylation of downstream substrates such as myosin light chain (MLC) and LIM kinase (Dian et al., 2025). By blocking ROCK-mediated phosphorylation events, Y-27632 disrupts stress fiber formation, focal adhesion assembly, and cytokinesis. The compound exhibits over 200-fold selectivity relative to other kinases, including PKC, PKA, MLCK, and PAK, minimizing off-target effects (APExBIO). As a cell-permeable ROCK inhibitor, Y-27632 is effective in both adherent and suspension cell models. The chemical is highly soluble in DMSO (≥111.2 mg/mL), ethanol (≥17.57 mg/mL), and water (≥52.9 mg/mL); solubility improves with warming or sonication. For further mechanistic detail, this related article offers a broad translational context, while the present article focuses on laboratory benchmarks and practical deployment.

    Evidence & Benchmarks

    • Y-27632 inhibits ROCK1 with an IC50 of approximately 140 nM, and ROCK2 with a Ki of 300 nM, demonstrating high selectivity and potency (APExBIO).
    • The compound exhibits over 200-fold selectivity versus PKC, PKA, MLCK, and PAK, reducing off-target signaling (MolecularBeacon.net).
    • In vitro, Y-27632 reduces prostatic smooth muscle cell proliferation in a concentration-dependent manner (notable at >10 µM, 37°C, serum-containing media) (Dian et al., 2025).
    • In mouse models, Y-27632 administration diminishes tumor invasion, reduces metastasis, and ablates pathological structures in KRAS-driven cancer settings (Dian et al., 2025).
    • Y-27632 enhances viability and colony formation efficiency in pluripotent stem cell culture protocols by inhibiting dissociation-induced apoptosis (G-418sulfate.com).
    • Stock solutions are stable at ≤-20°C for several months, but long-term storage in solution is not recommended due to gradual loss of activity (APExBIO).

    Applications, Limits & Misconceptions

    Y-27632 dihydrochloride is deployed in cancer research, stem cell biology, and cytoskeletal assays (FASC-terminal-tripeptide.com). It is a standard reagent for cell proliferation assays, inhibition of Rho-mediated stress fiber formation, and enhancement of stem cell viability. The compound is not a pan-kinase inhibitor and lacks significant effects on kinases outside the ROCK family at research-relevant concentrations. In KRAS-driven cancer studies, Y-27632 modulates tumor cell invasion but does not directly target KRAS or DDX3X (Dian et al., 2025), distinguishing it from agents like KRASG12C inhibitors or DDX3X degraders. Compared to this advanced insight article, the current dossier provides workflow-level detail on solubility and storage.

    Common Pitfalls or Misconceptions

    • Y-27632 is not effective against non-ROCK kinases; use alternative inhibitors for PKC, PKA, MLCK, or PAK targeting.
    • The compound does not directly inhibit Rho GTPase activity; it acts downstream at ROCK1/2.
    • Long-term storage of aqueous or DMSO solutions (>1 month) can reduce potency; always prepare fresh stocks when possible.
    • It is not suitable as a cytostatic agent in all tumor types; efficacy depends on ROCK pathway dependency.
    • Y-27632 does not substitute for genetic knockdown of ROCK1/2, as off-target effects (though minimal) may still occur at high concentrations.

    Workflow Integration & Parameters

    For most cell-based assays, Y-27632 is used at concentrations of 5–20 µM, with higher concentrations (up to 50 µM) reserved for robust cytoskeletal modulation. Stock solutions are prepared in DMSO (≥111.2 mg/mL), filtered, aliquoted, and stored at ≤-20°C. Warming at 37°C or ultrasonic bath treatment enhances solubility prior to use. The compound is supplied as a solid and should be stored desiccated at 4°C or below. Avoid repeated freeze-thaw cycles. For detailed protocols and troubleshooting, consult this workflow guide; the present article emphasizes stability and application boundaries. APExBIO's Y-27632 dihydrochloride (A3008) is validated for reproducibility across cytoskeletal, proliferation, and invasion assays.

    Conclusion & Outlook

    Y-27632 dihydrochloride is a gold-standard ROCK1/2 inhibitor with a robust evidence base, enabling precise modulation of Rho/ROCK signaling in diverse biological systems. Its high selectivity, cell permeability, and solubility profile make it indispensable for research into cytoskeletal dynamics, stem cell viability, and cancer cell invasion. The compound is best viewed as a tool for pathway dissection rather than a pan-cancer therapeutic. As new advances in Rho/ROCK pathway biology and cancer signaling emerge, Y-27632 will remain a foundational reagent for mechanistic and translational studies (Dian et al., 2025).